Veraxa Biotech AGNASDAQ: VRXA

VERAXA Biotech (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

· Issued by Veraxa Biotech AG

Summary by 6ix AI

VERAXA Biotech, which designs cancer therapies, presented its first in vivo (in a living model) proof-of-concept data and more in vitro (lab-based) findings for its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. ADC stands for antibody-drug conjugate.

Key details

  • VERAXA says the in vivo study showed tumor regression (shrinkage) in a breast cancer model after a single 3 mg/kg dose, with no observed decrease in body weight.
  • The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response.
  • VERAXA says the in vitro studies showed the platform could tell cancer cells from healthy cells, prevent active toxins from being released outside the tumor and target multiple cancer cell lines.
  • VERAXA says the findings support the potential of BiTAC-ADCs to work about as well as conventional antibody-drug conjugates, with a safety profile designed to reduce toxicity throughout the body.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/veraxa-biotech-nasdaq-vrxa-presents-first-in-vivo-proof-of-concept-data-for-bitac-adc-platform-at-world-adc-congress

Featured Image

Austin, Texas, United States, October 13th, 2026, NewsDirect

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response.

Additional in vitro studies demonstrated the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor and target multiple cancer cell lines. The findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates while offering a differentiated safety profile designed to reduce systemic toxicity.

To view the full press release, visit https://ibn.fm/cs8SW

About VERAXA Biotech AG

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA

Corporate Communications

IBN Austin, Texas www.IBN.ai 512.354.7000 Office Editor@IBN.ai

Contact
IBNwww.InvestorBrandNetwork.comEditor@InvestorBrandNetwork.com

Veraxa Biotech AG on 6ix

Story so far

Earlier from Veraxa Biotech

All Veraxa Biotech news releases